SCHEMBL15022855

SCHEMBL15022855

CS(=O)(=O)c1ccc(N[C@H]2CCN(C3CCN(c4ncc(C(F)(F)F)cc4Cl)CC3)C2=O)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 4/20 0.46
KCNH2 Q12809 3/20 0.46
GPR119 Q8TDV5 1/20 0.45
SMN1; SMN2 Q16637 5/20 0.44
LMNA P02545 2/20 0.44
HSD11B1 P28845 1/20 0.43
ALDH1A1 P00352 4/20 0.42
CYP2C9 P11712 3/20 0.42
CYP2C19 P33261 3/20 0.42
KDM4E B2RXH2 2/20 0.42
HPGD P15428 2/20 0.42
CHRM4 P08173 1/20 0.41
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
MAPT P10636 3/20 0.41
GAA P10253 1/20 0.41
CXCR3 P49682 1/20 0.41
CYP3A4 P08684 1/20 0.40
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15022856 1.00 SLC6A9 (0.46) SLC6A9KCNH2GPR119SMN1; SMN2LMNA
SCHEMBL15023673 0.95 SLC6A9 (0.45) SLC6A9KCNH2GPR119SMN1; SMN2LMNA
SCHEMBL15022743 0.93 SLC6A9 (0.46) SLC6A9KCNH2GPR119CXCR3
SCHEMBL12185832 0.93 SLC6A9 (0.46) SLC6A9KCNH2GPR119CXCR3
SCHEMBL15022662 0.90 GPR119 (0.44) SLC6A9KCNH2GPR119CYP2C9CYP3A4
SCHEMBL12185828 0.90 GPR119 (0.44) SLC6A9KCNH2GPR119CYP2C9CYP3A4
SCHEMBL15023430 0.90 SMN1; SMN2 (0.46) SLC6A9KCNH2SMN1; SMN2LMNAHSD11B1
SCHEMBL15023428 0.90 SMN1; SMN2 (0.46) SLC6A9KCNH2SMN1; SMN2LMNAHSD11B1
SCHEMBL15023204 0.89 SMN1; SMN2 (0.45) GPR119SMN1; SMN2LMNAALDH1A1CYP2C9
SCHEMBL12185830 0.89 SMN1; SMN2 (0.45) GPR119SMN1; SMN2LMNAALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754226-B2 Piperidinyl-substituted lactams as GPR119 modulators ARRAY BIOPHARMA INC. (US) 2014-06-17 US disclosed
US-8754226-B2 Piperidinyl-substituted lactams as GPR119 modulators ARRAY BIOPHARMA INC. (US) 2014-06-17 US disclosed
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2013-06-20 US disclosed
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS GPR119, GPR139, GPR39 SLC6A9 324/4885KCNH2 1430/4885GPR119 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.